LIGACHEM
LIVE

Serial Number

79408203

Owner

LigaChem Biosciences Inc.

Attorney

Richard Y. Kim

Filing Date

Aug 6, 2024

Add to watchlist:

No watchlists yet
View on USPTO

LIGACHEM Trademark

Serial Number: 79408203 • Registration: 7910368

LIGACHEM is a trademark filed by LigaChem Biosciences Inc. on August 6, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

LigaChem Biosciences Inc. (4 trademarks)

10, Gukjegwahak 10-ro, Yuseong-gu

Entity Type: 03

Trademark Details

Filing Date

August 6, 2024

Registration Date

August 26, 2025

Published for Opposition

June 10, 2025

Goods & Services

Vaccines; food supplements; vitamin preparations; crude medicines for treating cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; nutraceuticals for use as a dietary supplement; biological preparations for medical use for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical pharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; chemical preparations for medical use for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical molecular diagnostic reagents for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; biopharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; syrups for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medicated lozenges for pharmaceutical purposes; capsules sold empty for pharmaceuticals; chemico-pharmaceutical preparations for pharmaceutical or medical purposes, namely, for cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; antibodies for medical purposes; medical antibodies, especially antibody conjugates and active ingredients and antibody conjugates; chemical reagents for medical use, especially chemical reagents for linking molecules for medical use; pharmaceutical compositions for use in treatment and prevention of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; plant extracts, other than essential oils, for medicinal purposes; pharmaceutical preparations for cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets; pharmaceutical preparations for the treatment and prevention of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; antibiotics; anti-cancer preparations; mixed vitamin preparations; chemotherapeutics; pharmaceutical preparations for the treatment of rare cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 16, 2026 OPNX
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 2, 2026 FINV
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 30, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 29, 2026 OPNR
FINAL DISPOSITION NOTICE SENT TO IB
Mar 15, 2026 FICS
FINAL DISPOSITION PROCESSED
Mar 15, 2026 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 26, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 26, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 26, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 10, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 10, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 4, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 7, 2025 CNSA
REFUSAL PROCESSED BY IB
Apr 12, 2025 RFNT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 8, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 8, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 8, 2025 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 27, 2025 RFCS
REFUSAL PROCESSED BY MPU
Mar 27, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 21, 2025 RFCR
NON-FINAL ACTION WRITTEN
Feb 20, 2025 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Feb 19, 2025 ZZZX
WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST
Feb 19, 2025 PBSR
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 14, 2025 CNSA
ASSIGNED TO EXAMINER
Feb 12, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 12, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 12, 2024 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Nov 8, 2024 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 31, 2024 REPR